Emerging-Market Specialist Nycomed Acquires Majority Stake In China's Guangdong Techpool Bio-Pharma
This article was originally published in The Pink Sheet Daily
Executive Summary
Swiss Nycomed has acquired a majority stake in Guangdong Techpool Bio-Pharma for €210 million to expand its Chinese operations.
You may also be interested in...
Nycomed To Beef Up Sales In China Through Buyout; Bets On India For Global API Supplies
MUMBAI - Having established itself firmly among the top 10 pharma companies in Russia, Zurich-headquartered Nycomed now plans to dig deeper into the fast-growing Chinese market through the acquisition of a sales and distribution team
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.